Biohaven Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BHVN research report →
Range $11 – $48
Price Chart
About the company
Biohaven Ltd. , a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity.
- CEO
- Vladimir Coric
- IPO
- 2022
- Employees
- 274
- HQ
- New Haven, CT, US
Get TickerSpark's AI analysis on BHVN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.87B
- P/E
- -3.54
- Fwd P/E
- 12.08
- PEG
- -0.05
- P/S
- 0.00
- P/B
- -20.98
- EV/EBITDA
- -4.26
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -2271.87%
- ROIC
- -255.03%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-4,139,999+0.0%
- Op Income
- $-745,378,000
- Net Income
- $-738,822,000+12.7%
- EPS
- $-6.86+26.1%
- OCF Growth
- -4.6%
- FCF Growth
- -4.0%
- 52W High
- $18.24
- 52W Low
- $8.03
- 50D MA
- $13.43
- 200D MA
- $12.37
- Beta
- 3.13
- RSI (14)
- 41
- Avg Volume
- 3.23M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Biohaven capped 2021 with NURTEC ODT continuing to scale rapidly, while also adding new pipeline assets in epilepsy and SMA and expanding its global migraine strategy with Pfizer.· February 25, 2022
- NURTEC ODT net sales were $190 million in Q4 and $462.5 million for full-year 2021, with the quarter up 40% sequentially and 440% year over year.
- Management highlighted NURTEC as the number one prescribed migraine treatment in its class and said it has surpassed 1.6 million prescriptions since launch.
- Biohaven and Pfizer received a positive CHMP opinion in Europe for rimegepant, and management expects a China NDA filing later in 2022 after positive Asia data.
- The company announced two pipeline additions: BHV-7000 for epilepsy from Channel Biosciences and Taldefgrobep from Bristol Myers Squibb for SMA.
- CFO said Biohaven had about $1 billion of liquidity pro forma for the Pfizer transaction, and expects modest expense increases but no formal guidance yet.
NURTEC ODT generated $190 million in Q4 2021 net sales, up 40% versus Q3 and up 440% year over year. Full-year 2021 net sales were $462.5 million, up $399 million or 627% versus the prior year. Non-GAAP R&D was $76.4 million in Q4 versus $57.8 million in the prior quarter, and $287.1 million for 2021 versus $195.4 million in 2020. Non-GAAP SG&A was $189.3 million in Q4 versus $114 million in the prior quarter, and $623.6 million for 2021 versus $428.6 million in 2020. As of December 2021, Biohaven reported $367 million in cash and cash equivalents and marketable securities, $125 million immediate access from its Sixth Street debt facility, and $500 million received from Pfizer on January 4, for approximately $1 billion of liquidity pro forma. Management did not give formal revenue guidance; it said it cannot comment on the Street’s $850 million NURTEC estimate and expects modest increases in expenses, with guidance likely to come next year.
Vlad Coric framed the quarter as another standout period in an exceptional year, emphasizing that NURTEC has become the number one prescribed migraine treatment in its class and that the oral CGRP market still has room to expand materially. He was upbeat about the Pfizer collaboration, the positive CHMP opinion in Europe, and the China/Korea data, calling global expansion a major catalyst for building a world-class migraine business. He also stressed that Biohaven is broadening beyond migraine with new assets in epilepsy and SMA, describing the pipeline additions as higher-probability neuroscience opportunities that strengthen long-term value.
Matthew Buten focused on financial discipline, shareholder value, and getting to profitability while still funding growth. He cited Q4 NURTEC sales of $190 million, full-year sales of $462.5 million, and explained that the quarter’s strong performance benefited from higher volume, improved reimbursement, and favorable seasonality. On costs, he pointed to non-GAAP R&D of $76.4 million in Q4 and $287.1 million for 2021, plus non-GAAP SG&A of $189.3 million in Q4 and $623.6 million for the year, driven mainly by commercialization and pipeline expansion. He also detailed the Channel Biosciences deal terms: $65 million in Biohaven stock, $35 million in cash, up to $325 million in U.S./EMA/Japan regulatory milestones for epilepsy, up to $250 million for additional geographies/indications, and up to $562.5 million in sales milestones, plus royalties.
Analysts pressed for color on 2022 revenue and spending, but management declined to give formal guidance and would not endorse the Street’s $850 million NURTEC view. The company said expenses should rise only modestly, while Vlad argued that NURTEC still has significant growth ahead and that new pipeline assets add to, rather than detract from, long-term value. Questions also focused on whether the company might split or divest assets; management said it would keep running the business to maximize investor returns and did not rule in or out strategic alternatives. On the new programs, management said BHV-7000 will first pursue adult refractory focal epilepsy, while also exploring pediatric epilepsies such as KCNQ2 encephalopathic epilepsy, and Taldefgrobep in SMA will likely be tested with standard-of-care therapy because myostatin blockade may work synergistically with existing SMN-upregulating treatments.
The call showed strong commercial momentum, with NURTEC still growing rapidly and management saying the oral CGRP class is only early in its market penetration. Biohaven also secured a major ex-U.S. partner in Pfizer and got a positive CHMP opinion, which broadens the migraine opportunity beyond the U.S. The pipeline additions provide multiple shots on goal in neuroscience and rare disease, and management described both as differentiated, potentially higher-probability assets.
Management repeatedly declined to provide formal guidance, which leaves uncertainty around 2022 revenue and spending. Several Q4 tailwinds were described as seasonal or temporary, and management warned that Q1 could see typical sequential softness as deductibles reset and refill patterns normalize. Investors also raised concerns that expanding the pipeline could increase spending and complicate valuation, and the new assets still need clinical validation in indications where prior programs have mixed histories.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 85.1%
- Shares Outstanding
- 151.06M
- Float Shares
- 128.57M
of shares held by institutions
310 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Janus Henderson Group Ltd. | 17.53M | ▲ 16.13M |
| Blackrock, Inc. | 12.95M | ▼ 259.40K |
| Montanova Capital, LLC | 10.29M | 0 |
| Stifel Financial Corp | 9.94M | ▲ 520 |
| Jupiter Topco LLC | 8.58M | ▲ 8.58M |
| Woodline Partners LP | 7.66M | ▲ 7.36M |
| State Street Corp | 6.87M | ▼ 72.31K |
| Infinitum Asset Management, LLC | 6.25M | 0 |
| Vanguard Group Inc | 4.40M | ▲ 1.52M |
| D. E. Shaw & Co., Inc. | 4.19M | ▲ 1.34M |
| Aqr Capital Management LLC | 4.15M | ▲ 2.18M |
| Ubs Group AG | 2.94M | ▲ 418.69K |
Held by 235 ETFs
Biggest fund positions in BHVN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 15, 26 | Gentile Kimberly | other | 1,000 |
| Aug 6, 26 | Yetimoglu John | other | 0 |
| Jul 9, 26 | Volles Warren Karl | other | 0 |
| Jul 9, 26 | Volles Warren Karl | other | 0 |
| Jul 9, 26 | Volles Warren Karl | other | 0 |
| Jul 9, 26 | Volles Warren Karl | other | 0 |
| Jul 9, 26 | Volles Warren Karl | other | 0 |
| Jul 9, 26 | Volles Warren Karl | other | 0 |
| Jul 9, 26 | Volles Warren Karl | other | 0 |
| Apr 28, 26 | Mehta Kishan | other | 68,693 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BHVN coverage
Recent articles, reports, and earnings notes.
Want a deeper read on BHVN?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Biohaven Stock Climbs On Early Cancer Data
benzinga.com · Nov 19
Biohaven's Novel FGFR3-Directed ADC with Proprietary TopoIx Payload, BHV-1530, Shows Clinical Activity and Confirmed Responses in FGFR3-Altered Urothelial and Head and Neck Cancers, Oral Presentation at ENA 2026
prnewswire.com · Nov 19
Biohaven Drives New Research in Graves' Disease: Phase 3 Pivotal Trial with BHV-1300 Underway and Three Scientific Posters at the 2026 American Thyroid Association Annual (ATA) Meeting
prnewswire.com · Nov 5
Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results
prnewswire.com · Oct 29
Wall Street Analysts Believe Biohaven Ltd. (BHVN) Could Rally 43.49%: Here's is How to Trade
zacks.com · Oct 29
Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remove the Autoantibodies that Drive Membranous Nephropathy
prnewswire.com · Oct 26
Biohaven Stock Heads for Best Day in 3 Years as FDA Agrees to Review Drug Again
barrons.com · Oct 22
Biohaven Rebounds With FDA Review Date for Rare Disease Drug
benzinga.com · Oct 22
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
